

## Special Issue

# Targeting RNA to Improve Cancer Precision Medicine

### Message from the Guest Editors

RNA therapeutics are increasingly changing the standard of care for many diseases, including cancer, moving it toward personalized medicine. The development of RNA drugs is rapidly evolving and encompasses different classes of therapeutics, such as antisense oligonucleotides, aptamers, siRNAs, miRNAs, and mRNA. The main advantages in the use of RNA-based drugs are represented by the simple and cost-effective production, the ability to act on “undruggable” targets, and the speed in obtaining specific constructs for customised treatments.

The improvement and innovation of delivery strategies, mostly introducing chemical modifications on nucleic acid backbone and ribose ring, also coupled with the employment of advanced nanocarriers, represent the primary objectives of the current and future research of RNA-based drugs, which are going to find proficient application in oncology, revolutionising the gold standard for therapeutic interventions.

---

### Guest Editors

Dr. Gabriella Misso

Dr. Anna Grimaldi

Dr. Chiara Tammaro

---

### Deadline for manuscript submissions

30 September 2026



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/213239](https://mdpi.com/si/213239)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)